Arcutis Biotherapeutics Inc

NASDAQ:ARQT  
25.72
+0.17 (+0.66%)
Products, Regulatory

Arcutis Says Positive Topline Data From Phase 2 Clinical Trial Evaluating Arq-154 As A Potential Treatment For Seborrheic Dermatitis

Published: 09/29/2020 12:57 GMT
Arcutis Biotherapeutics Inc (ARQT) - Arcutis Announces Positive Topline Data From Phase 2 Clinical Trial Evaluating Arq-154 (topical Roflumilast Foam) As a Potential Treatment for Seborrheic Dermatitis.
Arcutis - Roflumilast Foam Demonstrated Statistically Significant Improvement Over Vehicle Foam on Trial's Primary and Multiple Secondary Endpoints.
Arcutis Biotherapeutics Inc - Once-daily Roflumilast Foam Demonstrated a Favorable Safety and Tolerability Profile.